Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 31.7% in July

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 403,000 shares, a decline of 31.7% from the June 30th total of 590,000 shares. Based on an average daily volume of 267,500 shares, the days-to-cover ratio is presently 1.5 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vincerx Pharma stock. Vanguard Group Inc. increased its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 29.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 666,995 shares of the company’s stock after acquiring an additional 153,575 shares during the period. Vanguard Group Inc. owned approximately 3.12% of Vincerx Pharma worth $3,375,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 44.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vincerx Pharma in a report on Tuesday, April 9th.

Vincerx Pharma Price Performance

Shares of VINC stock traded down $0.04 during trading hours on Monday, hitting $0.64. The stock had a trading volume of 67,166 shares, compared to its average volume of 804,945. Vincerx Pharma has a one year low of $0.57 and a one year high of $9.37. The stock’s 50-day moving average price is $0.68 and its two-hundred day moving average price is $2.01. The stock has a market capitalization of $19.10 million, a price-to-earnings ratio of -0.38 and a beta of 1.47.

Vincerx Pharma (NASDAQ:VINC) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). As a group, equities research analysts predict that Vincerx Pharma will post -0.62 earnings per share for the current fiscal year.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.